Among AbbVie's biggest risks is significant future uncertainty from two areas. First of all, AbbVie's current blockbuster drug, Humira, loses patent protection in the U.S. in 2016 and in the EU in 2018. The other source of uncertainty lies in AbbVie's pipeline, which is focused on a hepatitis C treatment. Its long-term profit potential might not be as much as expected, and the company will likely have to battle rival Gilead Sciences in this new market.
Follow along in the video below as Fool health care bureau chief Brenton Flynn runs through these risks in more detail.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What AbbVie's Management Just Said About Its Future
The manufacturer of the world's best-selling drug is offering up a very optimistic forecast.
7 Must-See Numbers From AbbVie's J. P. Morgan Presentation
AbbVie CEO Rick Gonzalez called the biotech "a unique investment opportunity." These numbers show why he's right.
Is AbbVie Stock Still A Strong Buy?
AbbVie's shares crushed the broader markets in 2017. Can this top biopharma stock keep pushing higher this year?